Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lipocine: Q3 Earnings Snapshot AP - Thu Nov 7, 5:25AM CST

Lipocine: Q3 Earnings Snapshot

LPCN : 4.90 (+2.04%)
Lipocine: Q2 Earnings Snapshot AP - Thu Aug 8, 5:32AM CDT

Lipocine: Q2 Earnings Snapshot

LPCN : 4.90 (+2.04%)
Lipocine: Q1 Earnings Snapshot AP - Thu May 9, 5:24AM CDT

Lipocine: Q1 Earnings Snapshot

LPCN : 4.90 (+2.04%)
Lipocine: Q3 Earnings Snapshot AP - Wed Nov 8, 2023

Lipocine: Q3 Earnings Snapshot

LPCN : 4.90 (+2.04%)
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr....

LPCN : 4.90 (+2.04%)
Lipocine: Q2 Earnings Snapshot AP - Thu Aug 10, 2023

Lipocine: Q2 Earnings Snapshot

LPCN : 4.90 (+2.04%)
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire - Thu Aug 10, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial...

LPCN : 4.90 (+2.04%)
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire - Thu Jul 27, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.90 (+2.04%)
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire - Wed Jun 14, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.90 (+2.04%)
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire - Wed Jun 7, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.90 (+2.04%)

Barchart Exclusives

Truist Analysts Love This Dividend Stock With a 15% Yield Barchart - Tue Dec 24, 6:30PM CST
Truist analysts are bullish on Mach Natural Resources (MNR), a new energy stock offering a 15% dividend yield and 45.5% upside potential. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot